Your browser doesn't support javascript.
loading
Screening for Breast Cancer: US Preventive Services Task Force Recommendation Statement.
Nicholson, Wanda K; Silverstein, Michael; Wong, John B; Barry, Michael J; Chelmow, David; Coker, Tumaini Rucker; Davis, Esa M; Jaén, Carlos Roberto; Krousel-Wood, Marie; Lee, Sei; Li, Li; Mangione, Carol M; Rao, Goutham; Ruiz, John M; Stevermer, James J; Tsevat, Joel; Underwood, Sandra Millon; Wiehe, Sarah.
Afiliação
  • Nicholson WK; George Washington University, Washington, DC.
  • Silverstein M; Brown University, Providence, Rhode Island.
  • Wong JB; Tufts University School of Medicine, Boston, Massachusetts.
  • Barry MJ; Harvard Medical School, Boston, Massachusetts.
  • Chelmow D; Virginia Commonwealth University, Richmond.
  • Coker TR; University of Washington, Seattle.
  • Davis EM; University of Maryland School of Medicine, Baltimore.
  • Jaén CR; The University of Texas Health Science Center, San Antonio.
  • Krousel-Wood M; Tulane University, New Orleans, Louisiana.
  • Lee S; University of California, San Francisco.
  • Li L; University of Virginia, Charlottesville.
  • Mangione CM; University of California, Los Angeles.
  • Rao G; Case Western Reserve University, Cleveland, Ohio.
  • Ruiz JM; University of Arizona, Tucson.
  • Stevermer JJ; University of Missouri, Columbia.
  • Tsevat J; The University of Texas Health Science Center, San Antonio.
  • Underwood SM; University of Wisconsin, Milwaukee.
  • Wiehe S; Indiana University, Bloomington.
JAMA ; 331(22): 1918-1930, 2024 06 11.
Article em En | MEDLINE | ID: mdl-38687503
ABSTRACT
Importance Among all US women, breast cancer is the second most common cancer and the second most common cause of cancer death. In 2023, an estimated 43 170 women died of breast cancer. Non-Hispanic White women have the highest incidence of breast cancer and non-Hispanic Black women have the highest mortality rate.

Objective:

The USPSTF commissioned a systematic review to evaluate the comparative effectiveness of different mammography-based breast cancer screening strategies by age to start and stop screening, screening interval, modality, use of supplemental imaging, or personalization of screening for breast cancer on the incidence of and progression to advanced breast cancer, breast cancer morbidity, and breast cancer-specific or all-cause mortality, and collaborative modeling studies to complement the evidence from the review. Population Cisgender women and all other persons assigned female at birth aged 40 years or older at average risk of breast cancer. Evidence Assessment The USPSTF concludes with moderate certainty that biennial screening mammography in women aged 40 to 74 years has a moderate net benefit. The USPSTF concludes that the evidence is insufficient to determine the balance of benefits and harms of screening mammography in women 75 years or older and the balance of benefits and harms of supplemental screening for breast cancer with breast ultrasound or magnetic resonance imaging (MRI), regardless of breast density. Recommendation The USPSTF recommends biennial screening mammography for women aged 40 to 74 years. (B recommendation) The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening mammography in women 75 years or older. (I statement) The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of supplemental screening for breast cancer using breast ultrasonography or MRI in women identified to have dense breasts on an otherwise negative screening mammogram. (I statement).
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Mamografia / Detecção Precoce de Câncer Limite: Adult / Aged / Female / Humans / Middle aged País/Região como assunto: America do norte Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Mamografia / Detecção Precoce de Câncer Limite: Adult / Aged / Female / Humans / Middle aged País/Região como assunto: America do norte Idioma: En Ano de publicação: 2024 Tipo de documento: Article